In the near future, two drugs will immediately receive registration certificates: T-Mab (Trastuzumab) and B-Mab (Bevacizumab). T-Mab and B-Mab are the first drugs registered by NatiVita outside Belarus.

NatiVita has registered drugs in Moldova

NatiVita has registered the first medicinal products in the Republic of Moldova. In the near future, two drugs will immediately receive registration certificates: T-Mab (Trastuzumab) and B-Mab (Bevacizumab). T-Mab and B-Mab are the first drugs registered by NatiVita outside Belarus.

Reference
T-Mab (Trastuzumab) — monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat HER2 positive (HER2+) certain breast and stomach cancers. Trastusumab increases the overall survival of patients with breast and stomach cancer, prolongs disease-free survival and improves the quality of life. Local production of Trastusumab` biosimilar will increase the availability of personalized therapy and will allow to save patients’ lives.

B-Mab (Bevacizumab) — drug that slows the growth of new blood vessels. Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Bevacizumab is approved to treat metastatic colorectal cancer, metastatic HER2-negative breast cancer, certain lung cancer, metastatic kidney cancer, ovarian and cervical cancers. Bevacisumab` inclusion into chemotherapy regimens significantly improves the effectiveness of treatment